GlassScriptPhysician profile
Deborah B Moore
NPI 1285700443
$3,420.70
in general payments reported to CMS, 2019-2025
23 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $941 · 2022: $958 · 2023: $758 · 2024: $462 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,522.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,053.73 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $697.59 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $344.88 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $336.52 | 2021-2025 | Caplyta |
| Glaxosmithkline, LLC. | $298.17 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $176.05 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $69.98 | 2022 | |
| Novartis Pharmaceuticals Corporation | $53.90 | 2022 | |
| Halozyme INC | $49.78 | 2023 | |
| Sanofi-Aventis U.S. LLC | $47.88 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $45.73 | 2023 | Seglentis |
| Lilly USA, LLC | $32.19 | 2021-2022 | |
| Axsome Therapeutics, INC. | $31.74 | 2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $27.81 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $25.00 | 2023 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $20.53 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $18.29 | 2024 | Xarelto |
| Amarin Pharma, INC. | $18.04 | 2021 | |
| Metacel Pharmaceuticals LLC | $15.50 | 2023 | Ozobax |
| Amgen INC. | $14.99 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.91 | 2021 | |
| Mylan Specialty L.P. | $14.86 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.